Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3223 participants
OBSERVATIONAL
2013-07-19
2017-08-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis
NCT02425462
Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life
NCT01595724
Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients
NCT01822080
Visanne Post-approval Observational Study (VIPOS)
NCT01266421
Safety and Efficacy of SH T00660AA in Treatment of Endometriosis
NCT00225186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Dienogest (Visanne, BAY86-5258)
Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dienogest (Visanne, BAY86-5258)
Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women diagnosed by a physician as having endometriosis
* Women who are prescribed Visanne(dienogest 2mg)for the first time during the study period
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple Locations, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VS1310KR
Identifier Type: OTHER
Identifier Source: secondary_id
16625
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.